Lynch Regenerative Medicine Completes Series A Financing

Company Brings Proven Skin Rejuvenation and Regeneration Solutions to the Global Skin Care Market

FRANKLIN, Tenn.--(BUSINESS WIRE)--Lynch Regenerative Medicine, LLC (LRM) has completed its Series A financing to develop and commercialize innovative skin rejuvenation and regeneration solutions based on the only tissue growth factor that has been approved by the FDA and other international regulator bodies to be safe and effective in human tissue regeneration and wound healing, pure platelet-derived growth factor (PDGF). LRM’s Series A financing round was led by Champion VC, a family office investor managing the assets of members of the Frist family of Nashville, Tennessee, and Dr. Samuel Lynch, founder and CEO of LRM.

The patented pure PDGF-based technology is currently the main active component in four FDA-approved products, including two products for improving healing and regeneration of orthopedic tissues, and one product each for improving the healing and regeneration of periodontal tissues and skin. These products have helped millions of patients around the world over the past 15 years. Now LRM is applying this proven technology to skin aesthetics.

Dr. Lynch is among the most successful founders and CEOs of regenerative medicine companies, with LRM being his third company to introduce pure PDGF-based products to the market. Skincare represents the largest and fastest-growing market segment for this technology to date. The market has a need for safe, effective and proven solutions to rejuvenate and regenerate healthy skin tissue.

Dr. Lynch, who is recognized worldwide as one of the leading experts on tissue growth factors, commented, “I’ve spent my career studying regenerative medicine and developing and commercializing PDGF products to regenerate tissues lost due to trauma or disease. I’m most excited to bring pure PDGF-based solutions to the skincare market, where we see the largest unmet need for proven solutions for skin rejuvenation and regeneration.”

LRM’s first product to improve skin aesthetics, Ariessence™ Pure PDGF+ (www.ariessence.com), is available today and can be found in leading innovative med/spa clinics and other aesthetic-focused offices, including dermatology and plastic surgery practices. Ariessence Pure PDGF+ is used topically to improve aesthetic outcomes associated with procedures such as micro-needling, dermabrasion, lasers, plastic surgery and other procedures where the appearance of healthier-looking skin can be accelerated and enhanced using growth factors such as PDGF.

“Growth factors are playing an important role in skincare today, but there are no other solutions backed by the level of scientific and clinical evidence that supports the safety and effectiveness of pure PDGF,” said Lynch. “Arriessence Pure PDGF+ builds on this truly unique foundation of success in regenerative medicine.”

LRM will use the capital from the Series A financing to fuel its commercialization strategy. With the successful closing of this Series A round, LRM plans to expand its team, bringing in additional top-tier talent across various disciplines, including commercialization, business development, clinical development, and regulatory affairs.

PH Partners acted as financial advisors to LRM, and Bass, Berry & Sims acted as legal counsel in connection with the transaction.

Lynch Regenerative Medicine, LLC is pioneering innovative treatments that aim to revolutionize the $100 billion aesthetics and wound-care markets. Our mission is to leverage our regenerative medicine heritage, and our decades-long commitment to safe and effective regenerative products of the highest quality, to deliver exceptional results for our customers and their patients and thereby redefine the future of aesthetic regenerative medicine. The company was founded in 2023 and is based in Franklin, Tennessee.